1

Hervorragende Patientenergebnisse

Orsiro wurde 2011 ins Leben gerufen und verfügt über ein umfangreiches klinisches Programm mit mehr als 48.500 eingeschlossenen Patienten. Orsiro Mission verwendet das klinisch erprobte Orsiro DES für ein völlig neues Liefersystem.

BIOFLOW-V

5-year results: Orsiro - pushing the boundaries of safety performance*3

orsiro_36_lower_tv-mi_graphic

TLF – Target Lesion Failure; TV-MI - Target Vessel Myocardial Infarction; ST – Stent Thrombosis
​​​​​​​​​​​​​​

BIOSTEMI

Continued Superiority of Orsiro over Xience in STEMI patients at 2 years4**

CO-PRINCIPAL INVESTIGATOR OF THE BIOSTEMI RCT DISCUSSES KEY FINDINGS AT 2-YEAR FOLLOW UP

Juan F. Iglesias, MD, Geneva, Switzerland

“The Orsiro stent should now be considered as the benchmark stent for stent comparison mainly in patients with ACS and STEMI”
Juan F. Iglesias, MD, Geneva, Switzerland

ACS – Acute Coronary Syndrome, STEMI – ST segment-Elevation Myocardial Infarction

CO-PRINCIPAL INVESTIGATOR OF THE BIOSTEMI RCT DISCUSSES KEY FINDINGS AT 2-YEAR FOLLOW UP

Juan F. Iglesias, MD, Geneva, Switzerland

BIO-RESORT

Small Vessels. Ultrathin Struts. Big Difference5

BIO-RESORT: Small Vessels. Ultrathin Struts. Big Difference.

BIO-RESORT: Small Vessels. Ultrathin Struts. Big Difference.

1. In comparison to Xience Sierra, Resolute Onyx and Synergy for bench tests on pushability, trackability and crossability, BIOTRONIK data on file; 2. BIOTRONIK data on file, status January 2020; 3. Kandzari D et al. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents for Coronary Revascularization: Final 5-year Outcomes from the Randomized BIOFLOW V Trial, Submitted manuscript to JACC, 2022: NCT02389946. (All figures from submitted manuscript are rounded by Biotronik after the BIOFLOW-V figures presented by D. Kandzari, at CRT 2022, Washington, USA.); 4. Iglesias JF et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial; Lancet, September, 2019; 5. Buiten R et al. Outcomes in patients treated with thin-strut, very thin-strut, or ultrathin-strut drug-eluting stents in small coronary vessels - A prespecified analysis of the randomized BIO-RESORT trial; JAMA Cardiol. Published online May 21, 2019. doi:10.1001/jamacardio.2019.1776; ClinicalTrials.gov: NCT01674803. 
 
*Based on statistically significant lower TV-MI and late/very late definite/probable ST rates through 5 years for Orsiro DES vs Xience DP-EES in BIOFLOW-V. **Based on TLF rates from the BIOSTEMI trial. ∆ Posterior probability of superiority in STEMI in comparison to Xience at 24 months with respect to TLF, based on combined data set of BIOSTEMI and BIOSCIENCE STEMI groups.  


Resolute, Resolute Onyx and Integrity are trademarks or registered trademarks of the Medtronic Group of Companies. Xience and Xience Sierra are trademarks or registered trademarks of the Abbott Group of Companies.

Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies.

Disclaimer                                                                                                                                                                                                                 Clinical data conducted with Orsiro, Orsiro Mission’s predecessor device can be used to illustrate Orsiro Mission clinical outcomes.

© 2022 BIOTRONIK AG – All rights reserved.                                                                                                                             Specifications are subject to modification, revision and improvement.